← My Government dashboard

Government Watch

Dossier Legislative introduced 21-jul-2026
Bill introduced in Congress — not yet passed by either chamber, and not law.

A bill to amend the Public Health Service Act to streamline the review of biosimilar biological products.

Key claim: Senate bill S5059 would amend the Public Health Service Act to streamline the review of biosimilar biological products.

Abstract

(S5059 · 119th Congress) Latest action (2026-07-21): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Why this matters

Biosimilar competition is a primary mechanism for lowering the cost of high-priced biologic drugs in Medicare, Medicaid, and commercial coverage. Procedural reforms to FDA’s biosimilar review pathway can affect how quickly lower-cost alternatives reach patients and payers, though at the introduction stage the bill’s specific streamlining mechanism is not yet public.

Source

Link

Briefing card

A bill to amend the Public Health Service Act to streamline the review of biosimilar biological products.
Stage: introduced · congress · 21-jul-2026

Senate bill S5059 would amend the Public Health Service Act to streamline the review of biosimilar biological products.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: congress:119-s-5059:introduced

Ask about this finding

Replies are grounded in the abstract and metadata above. The model will quote directly when possible and say so if a question isn't covered.

Stages other doctrine resolution introduced proposed rule passed chamber executive action final rule enacted district opinion circuit opinion opinion

Subscribe: calendar of upcoming dates · deadlines feed · all new records

build build 392 · ea9c128-dirty · 2026-08-09